Acute Myeloid Leukemia

Resource	Address
Büchner T, Schlenk RF, Schaich M, et al. Acute myeloid leukemia (AML): Different treatment strategies versus a common standard arm—combined prospective analysis by the German AML Intergroup. *J Clin Oncol*. 2012;30(29):3604-3610.	https://pubmed.ncbi.nlm.nih.gov/22965967/
Burnett AK, Hills RK, Russell. Twenty five years of UK trials in acute myeloid leukaemia: What have we learned? *Br J Haematol*. 2020;188(1):86-100.	https://pubmed.ncbi.nlm.nih.gov/31828788/
Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. *Lancet*. 2012;379(9825):1508-1516.	https://pubmed.ncbi.nlm.nih.gov/22482940/
Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia*. 2019;33(2):379-389.	https://pubmed.ncbi.nlm.nih.gov/30555165/
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med*. 2020;383(7):617-629.	https://pubmed.ncbi.nlm.nih.gov/32786187/
DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in *IDH1*-mutated relapsed or refractory AML. *N Engl J Med*. 2018;378(25):2386-2398.	https://pubmed.ncbi.nlm.nih.gov/29860938/
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.	https://pubmed.ncbi.nlm.nih.gov/27895058/
Gottesman MM. Mechanisms of cancer drug resistance. *Annu Rev Med*. 2002;53:615-627.	https://pubmed.ncbi.nlm.nih.gov/11818492/
Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: A meta-analysis of individual patient data from randomised controlled trials. *Lancet Oncol*. 2014;15(9):986-996.	https://pubmed.ncbi.nlm.nih.gov/25008258/
Irish W, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. Acute myeloid leukemia: A retrospective claims analysis of resource utilization and	https://pubmed.ncbi.nlm.nih.gov/27966377/

expenditures for newly diagnosed patients from first-line induction to remission and relapse. *Curr Med Res Opin*. 2017;33(3):519-527.	
Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. *Clin Cancer Res*. 2009;15(4):1126-1132.	https://pubmed.ncbi.nlm.nih.gov/19228717/
Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. *Blood*. 2014;123(21):3239-3246.	https://pubmed.ncbi.nlm.nih.gov/24687088/
Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. *J Clin Oncol*. 2018;36(26):2684-2692.	https://pubmed.ncbi.nlm.nih.gov/30024784/
Levis M. Targeting IDH: The next big thing in AML. *Blood*. 2013;122(16):2770-2771.	https://pubmed.ncbi.nlm.nih.gov/24136078/
Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. *Mol Cancer Ther*. 2006;5(7):1854-1863.	https://pubmed.ncbi.nlm.nih.gov/16891472/
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. *N Engl J Med*. 1994;331(14):869-903.	https://pubmed.ncbi.nlm.nih.gov/8078551/
O'Donnell MR, Tallmann MS, Abboud CN, et al. Acute myeloid leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017;15(7):926-957.	https://pubmed.ncbi.nlm.nih.gov/28687581/
Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era? *Cancer*. 2011;117(15):3293-3304.	https://pubmed.ncbi.nlm.nih.gov/21319142/
Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory *FLT3*-mutated AML. *N Engl J Med*. 2019;381(18):1728-1740.	https://pubmed.ncbi.nlm.nih.gov/31665578/
Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: A literature review. *Cancer Treat Rev*. 2004;30(3):237-247.	https://pubmed.ncbi.nlm.nih.gov/15059647/

Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed *IDH1*-mutant acute myeloid leukemia. *Blood*. 2020;135(7):463-471.	https://pubmed.ncbi.nlm.nih.gov/31841594/
Roboz GJ, Montesinos P, Selleslag D, et al. Design of the randomized, phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. *Future Oncol*. 2016;12(3):293-302.	https://pubmed.ncbi.nlm.nih.gov/26785287/
Savona MR, Kolibaba K, Conkling P, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. *Am J Hematol*. 2018;93(10):1199-1206.	https://pubmed.ncbi.nlm.nih.gov/30016552/
Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant *IDH2* relapsed or refractory acute myeloid leukemia. *Blood*. 2017;130(6):722-731.	https://pubmed.ncbi.nlm.nih.gov/28588020/
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a *FLT3* mutation. *N Engl J Med*. 2017;377(5):454-464.	https://pubmed.ncbi.nlm.nih.gov/28644114/
Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. *N Engl J Med*. 2020;383(26):2526-2537.	https://pubmed.ncbi.nlm.nih.gov/33369355

Chronic Lymphocytic Leukemia

Resource	Address
Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicenter, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2020;21(9):1188-1200.	https://pubmed.ncbi.nlm.nih.gov/32888452/
Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med*. 2000;343(26):1910-1916.	https://pubmed.ncbi.nlm.nih.gov/11136261/
Eichhorst B, Niemann C, Kater AP, et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First co-primary endpoint analysis of the International Intergroup GAIA (CLL13) Trial. *Blood*. 2021;138(suppl 1):71.	https://ashpublications.org/blood/article/138/Supplement%201/71/477548/A-Randomized-Phase-III-Study-of-Venetoclax-Based

Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med*. 2019;380(23):2225-2236.	https://pubmed.ncbi.nlm.nih.gov/31166681/
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*. 2008;111(12):5446-5456.	https://pubmed.ncbi.nlm.nih.gov/18216293/
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood*. 1999;94(6):1848-1854.	https://pubmed.ncbi.nlm.nih.gov/10477713/
Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicenter, open-label, phase 2 trial. *Lancet Oncol*. 2018;19(1):65-75.	https://pubmed.ncbi.nlm.nih.gov/29246803/
Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. *J Clin Oncol*. 2020;38(34):4042-4054.	https://pubmed.ncbi.nlm.nih.gov/32986498/
Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*. 2018;378(12):1107-1120.	https://pubmed.ncbi.nlm.nih.gov/29562156/